
Aurinia Pharmaceuticals Inc
-3.2 %
47.61 %
Yet to be announced
Company Overview
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat serious diseases, primarily in nephrology and autoimmune diseases. Their main product is LUPKYNIS™ (voclosporin), an oral therapy for adult patients with active lupus nephritis (LN), which was approved by the FDA in January 2021.
Revenue Sources
PassBased on SEC filings and company reports, Aurinia's revenue primarily comes from sales of LUPKYNIS, which is a legitimate medical treatment. The company's business model focuses on developing and commercializing treatments for serious medical conditions, which is halal. There is no evidence of revenue from haram sources.
Reliance on Interest
Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Sept. 30, 2024 | $67.77m | $57.23m | - | $1.21m | 0.00% | 2.11% |
June 30, 2024 | $57.19m | $59.9m | - | $1.2m | 0.00% | 2.00% |
March 31, 2024 | $50.3m | $64.84m | - | $1.28m | 0.00% | 1.98% |
Dec. 31, 2023 | $45.09m | $74.77m | - | - | 0.00% | 0.00% |
Looking at the past four quarters, interest expenses have been consistently low relative to total expenses. The interest expense ratios range from negligible to minimal percentages of total expenses, staying well below concerning levels. The company's interest expenses are primarily related to operational financing rather than interest-based business activities.
Operational Ethics
PassAfter reviewing company documents, public records, and operational locations, there is no evidence of material ongoing associations with entities involved in human rights violations. The company's main operations are in North America, with no significant presence or partnerships in regions of concern.
Login to join the discussion